Nuvation Bio’s IBTROZI Hits 50-Month Response in ROS1+ NSCLC
Nuvation Bio’s updated TRUST-I and TRUST-II clinical data show that IBTROZI achieved a median duration of response of 50 months in tyrosine kinase inhibitor–naïve ROS1-positive NSCLC patients. Additional results in TKI-pretreated patients demonstrate sustained efficacy and a manageable safety profile.
1. AACR 2026 Presentations
Nuvation Bio will showcase pivotal IBTROZI data at the American Association for Cancer Research Annual Meeting in San Diego from April 17 to 22, 2026. Oral presentations on April 21 (2:30–4:30 p.m. PST) will cover TKI-naïve patients, while poster sessions (2:00–5:00 p.m. PST) will detail TKI-pretreated results.
2. TKI-Naïve Patient Data
Updated TRUST-I and TRUST-II results reveal a median duration of response of 50 months in tyrosine kinase inhibitor–naïve ROS1-positive NSCLC patients as of the August 2025 data cutoff, reflecting unprecedented durability.
3. TKI-Pretreated Patient Data
New efficacy and safety findings in patients previously treated with ROS1 TKIs indicate sustained antitumor responses and a manageable safety profile, with specific response rates and adverse event frequencies to be reported.
4. Broader Clinical Program
IBTROZI, approved for ROS1-positive NSCLC in June 2025, is under evaluation in multiple registrational studies, including ongoing global Phase 2 and Phase 3 trials, reinforcing Nuvation Bio’s advancement of next-generation ROS1 inhibitors.